Table 3. Proportions and odds ratio of anti-angiogenic diseases in relation to ONJ in the groups of patients taking bisphosphonates.
| Anti-angiogenic disease | Group 1A (n=32) | Group 1B (n=27) | Odds ratio | P-value | ||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
| DM | 6 (18.8) | 26 (81.3) | 5 (18.5) | 22 (81.5) | 1.01 | 0.982 |
| Hypertension | 13 (40.6) | 19 (59.4) | 15 (55.6) | 12 (44.4) | 0.55 | 0.254 |
| RA | 5 (15.6) | 27 (84.4) | 2 (7.4) | 25 (92.6) | 2.31 | 0.341 |
| Hyperlipidemia | 9 (28.1) | 23 (71.9) | 4 (14.8) | 23 (85.2) | 2.25 | 0.226 |
| More than 1 disease | 24 (75.0) | 8 (25.0) | 17 (63.0) | 10 (37.0) | 1.76 | 0.319 |
(ONJ: osteonecrosis of the jaw, DM: diabetes mellitus type II, RA: rheumatoid arthritis, More than 1 disease: existence of more than one of the antiangiogenic diseases mentioned above)
Group 1A: bisphosphonate-related osteonecrosis of the jaw (BRONJ) group, Group 1B: non-BRONJ group.